Amedisys Beats on Revenue, Matches Expectations on EPS
Amedisys (NAS: AMED) reported earnings on May 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Amedisys beat slightly on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue improved slightly and GAAP earnings per share contracted significantly.
Margins dropped across the board.
Amedisys chalked up revenue of $370.8 million. The 12 analysts polled by S&P Capital IQ expected a top line of $366.6 million on the same basis. GAAP reported sales were 1.8% higher than the prior-year quarter's $364.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.22. The 12 earnings estimates compiled by S&P Capital IQ forecast $0.22 per share. GAAP EPS of $0.18 for Q1 were 66% lower than the prior-year quarter's $0.53 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 43.8%, 370 basis points worse than the prior-year quarter. Operating margin was 3.4%, 410 basis points worse than the prior-year quarter. Net margin was 1.5%, 270 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $370.3 million. On the bottom line, the average EPS estimate is $0.24.
Next year's average estimate for revenue is $1.49 billion. The average EPS estimate is $1.01.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 838 members out of 933 rating the stock outperform, and 95 members rating it underperform. Among 229 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 192 give Amedisys a green thumbs-up, and 37 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amedisys is hold, with an average price target of $12.10.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Amedisys prepared for the future? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Amedisys to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.